Results 81 to 90 of about 2,912 (169)

Activity of β-Lactamase Inhibitor Combinations Against Enterobacterales Isolated from Patients with Intra-Abdominal Infection from United States Medical Centres (2019–2023)

Antibiotics
Objective: To evaluate the antimicrobial susceptibility of Enterobacterales isolated from patients with intra-abdominal infections (IAI) in United States (US) medical centres.
Helio S. Sader, John H. Kimbrough, Marisa L. Winkler, Rodrigo E. Mendes, Mariana Castanheira   +4 more
doaj   +1 more source

Activity of aztreonam-avibactam and ceftazidime-avibactam against β-lactamase-producing enterobacterales Isolates from United States hospitals

Journal of Global Antimicrobial Resistance
Objectives: Enterobacterales isolates producing β-lactamases are widespread and threaten the use of β-lactams. This study evaluated the activity of aztreonam-avibactam and comparator antimicrobial agents against Enterobacterales isolates producing common
Lalitagauri M Deshpande, Timothy B Doyle, Helio S Sader, Mariana Castanheira   +3 more
doaj   +1 more source

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections—In Vitro Susceptibility Testing

Pharmaceuticals
Antimicrobial resistance is a major global health issue. Metallo-β-lactamases (MBL), in particular, are problematic because they can inactivate all classes of β-lactams except aztreonam.
Małgorzata Brauncajs, Filip Bielec, Marlena Malinowska, Dorota Pastuszak-Lewandoska   +3 more
doaj   +1 more source

Antimicrobial susceptibility of clinically important carbapenem-resistant Enterobacterales towards standard and new antibiotics

Journal of Global Antimicrobial Resistance
AIM: The aim of this work is to study carbapenem-resistant Enterobacterales (CRE) incidence, carbapenemase types and antimicrobial susceptibility of the strains to standard and new antibiotics.
Deniz Hamidov, Emma Keuleyan, Theodor Todorov, Radoslava Vazharova, Georgi Todorov, Atanas Syarov   +5 more
doaj   +1 more source

Cefiderocol in the Successful Treatment of Complicated Hospital-Acquired K. pneumoniae NDM, OXA48 Intraabdominal Infection

Infection and Drug Resistance
Ignacy Tarski,1 Jakub Śmiechowicz,2 Wiesława Duszyńska2 1Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland; 2Department and Clinic of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Wroclaw ...
Tarski I, Śmiechowicz J, Duszyńska W
doaj  

Outline of Meropenem-Vaborbactam for the Treatment of Carbapenem-Resistant Enterobacteriaceae

International Journal of Pharmaceutical Sciences Review and Research, 2023
Dr. Kush Nimron, Dr. Johncy Nathasha
openaire   +1 more source

Epidemiology and antimicrobial susceptibility profiles of Enterobacterales causing bloodstream infections before and during COVID-19 pandemic: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2018–2021

Journal of Microbiology, Immunology and Infection
Background: The coronavirus disease 2019 (COVID-19) pandemic has contributed to the spread of antimicrobial resistance, including carbapenem-resistant Enterobacterales.
Yu-Lin Lee, Chun-Eng Liu, Hung-Jen Tang, Yu-Tsung Huang, Yao-Shen Chen, Po-Ren Hsueh, Wen-Chien Ko, Po-Liang Lu, Chun-Eng Liu, Kenneth Yin-Ching Chuang, Fu-Der Wang, Yao-Shen Chen, Min-Chi Lu, Mao-Wang Ho   +13 more
doaj   +1 more source

Genomic and molecular characterisation of a KPC-producing Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam. [PDF]

BMC Genom Data
Wan Y, Wong JLC, Sanchez-Garrido J, Low WW, Turton JF, Morecchiato F, Baccani I, Dodgson K, Rossolini GM, Woodford N, Frankel G, Jauneikaite E, Meunier D, Hopkins KL.   +13 more
europepmc   +2 more sources

The Place of Meropenem–Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections [PDF]

Infectious Diseases and Therapy, 2021
openaire   +2 more sources

Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections. [PDF]

Antimicrob Agents Chemother
Karaba SM, Hareza DA, Munita JM, Martinez JRW, Bergman Y, Hawes AM, Bulman ZP, Cosgrove SE, Simner PJ, Tamma PD.   +9 more
europepmc   +1 more source